Investors in Demant A/S (CPH:DEMANT) had a good week, as its shares rose 2.2% to close at ø228 following the release of its yearly results. It looks like the results were a bit of a negative overall.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Demant benefits from favourable trends, including an ageing population, increasing noise pollution, fairly low penetration rates in the developed world, and virtually untapped patient populations in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The average one-year price target for Demant A (CPSE:DEMANT) has been revised to 236,37 kr. / share. This is a decrease of 12.07% from the prior estimate of 268,83 kr. dated February 1, 2026. The ...

The deal price is up to DKr600m The transaction is expected to take place no later than the end of Q1 2026 Demant is a hearing healthcare group based in Denmark Impilo has agreed to buy Oticon Medical ...

Oticon Medical’s ears must be burning after parent company Demant struck a deal to divest the implant business in a sale to fellow hearing technology developer Cochlear. Copenhagen-based Demant will ...

6.5.2025 17:20:20 CEST | Demant A/S | Inside information Company announcement no 2025-07 6 May 2025 Revised financial outlook for 2025 and Interim Management Statement for Q1 2025 Reduced expectations ...

Demant says does not want to take over Ossur Says offer for technical reasons COPENHAGEN, May 22 (Reuters) - Denmark's William Demant Invest A/S (WDI) made a bid on Tuesday for Icelandic prosthetics ...